A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint
BackgroundCD161, encoded by killer cell lectin-like receptor B1 gene, is a newly reported candidate inhibitor of tumour-infiltrating T cells. Antibody-mediated CD161 blockade enhances T cell-mediated killing of cancer cells in vitro and in vivo in several tumour types. We evaluated the role of CD161...
Main Authors: | Xiaohan Zhou, Jun Du, Chengdong Liu, Hanyi Zeng, Yuting Chen, Li Liu, Dehua Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-07-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.688215/full |
Similar Items
-
Characterization of hypoxia response patterns identified prognosis and immunotherapy response in bladder cancer
by: Rui Cao, et al.
Published: (2021-09-01) -
Targeting immune checkpoints in hematological malignancies
by: Basit Salik, et al.
Published: (2020-08-01) -
Pan‐cancer analysis identifies TERT alterations as predictive biomarkers for immune checkpoint inhibitors treatment
by: Tao Jiang, et al.
Published: (2020-06-01) -
The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
by: Florent Petitprez, et al.
Published: (2020-05-01) -
Research Progress of CD47-SIRPα Signaling Axis as An Innate Immune Checkpoint in Cancer
by: ZHA Li, et al.
Published: (2018-08-01)